No Data
No Data
No Data
Gan & Lee Pharmaceuticals. (SHSE:603087) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Gan & Lee Pharmaceuticals. (SHSE:603087) shares have had a horrible month, losing 30% after a relatively good period beforehand. To make matters worse, the recent drop has wiped out a year's worth
Some Confidence Is Lacking In Gan & Lee Pharmaceuticals.'s (SHSE:603087) P/S
When you see that almost half of the companies in the Biotechs industry in China have price-to-sales ratios (or "P/S") below 8.4x, Gan & Lee Pharmaceuticals. (SHSE:603087) looks to be giving off stron
Gan & Lee Pharmaceuticals Administers First Subject in Phase II Study of GZR101 Diabetes Drug
Gan & Lee Pharmaceuticals (SHA:603087) administered the first subject for the Phase II clinical trial of its type 2 diabetes drug, GZR101. The trial, which was approved by China's National Medical Pro
Insiders Own 33% of Gan & Lee Pharmaceuticals. (SHSE:603087) Shares but Individual Investors Control 41% of the Company
Key Insights Significant control over Gan & Lee Pharmaceuticals by individual investors implies that the general public has more power to influence management and governance-related decisions A tota
Gan & Lee Pharmaceuticals Gets Regulatory Nod for Private Placement
Gan & Lee Pharmaceuticals (SHA:603087) obtained approval from the China Securities Regulatory Commission to issue shares to specific investors. The Chinese pharmaceutical company is allowed to issue s
Shareholders in Gan & Lee Pharmaceuticals (SHSE:603087) Have Lost 12%, as Stock Drops 3.1% This Past Week
It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make higher profits, but you also face the risk of under-performance. Investors in Gan &
No Data